A consolidation of novel technologies in both the early diagnosis and treatment of sepsis
ASEP yields better treatment outcomes and decreased mortality for confirmed clinical cases of sepsis, and increases patients’ quality of life through the treatment of chronic infections with novel peptide drugs.
Sepsis kills 11 million people per year.
There is no current means to quickly identify, categorize and triage SEPSIS – a serious condition caused by an abnormal immune response to an infection. Today’s therapies comprise of old drug therapies and regimes that ultimately lead to infection resistance and lack of positive clinical outcomes.
ASEP Medical addresses both of these unmet clinical needs:
Early & Concise Diagnosis
A proprietary blood-test assessment of gene expression signatures, specific to the patient, that identifies early signals as to how their body is responding to certain types of infectious threats. Emergency room physicians will have a valuable tool to identify early signs of sepsis and to determine the degree of severity and probability of potential organ failure to determine how best to triage the patient for the best possible immediate care. This optimizes the sorting of patients by specific endotype*.
Novel Therapeutic Approach
A peptide technology that involves small potent broad-spectrum anti-biofilm and anti-inflammatory peptides that are highly active against all major clinically relevant infections, including antibiotic-resistant bacteria associated with biofilm infections. Additional peptide analogs are used to suppress harmful inflammation while boosting protective innate immunity; i.e., immune modulators.
A Diagnostic Tool for Sepsis & Covid-19
Our diagnostic tool, Sepset™, is a first-in-class point-of-care test to predict sepsis and organ failure in the general population and Covid-19 patients.